INABNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
IN8BIO, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$1.09−0.02 (-1.80%)
Close on Oct 19, 2026
- Market cap
- $21.22M
- P/E (TTM)
- –
- Dividend yield
- –
In8bio statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Biological Products, (No Diagnostic Substances) companies for comparison
Valuation
| Measure | In8bio | Industry median |
|---|---|---|
| Market Cap | $10.75M | $166.30M |
| Enterprise Value | -$7.21M | $88.19M |
| PB Ratio | 0.59 | 2.03 |
| P/TBV Ratio | 0.59 | 2.29 |
Income (trailing twelve months)
| Measure | In8bio | Industry median |
|---|---|---|
| Operating Income | -$18.67M | -$21.40M |
| Net Income | -$18.67M | -$22.46M |
| EBITDA | -$18.67M | -$16.91M |
| EPS (Diluted) | -$2.06 | -$0.83 |
Returns
| Measure | In8bio | Industry median |
|---|---|---|
| Return on Equity (ROE) | -111.1% | -53.2% |
| Return on Assets (ROA) | -90.8% | -40.9% |
| Return on Invested Capital (ROIC) | -1218.8% | -32.4% |
| Return on Capital Employed (ROCE) | -95.8% | -38.1% |
Balance sheet
| Measure | In8bio | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $17.96M | $61.43M |
| Net Cash (Debt) | $17.96M | $15.35M |
| Net Cash Per Share | $1.82 | $0.66 |
| Equity (Book Value) | $18.36M | $49.09M |
| Book Value Per Share | $1.86 | $1.37 |
| Tangible Book Value | $18.36M | $23.52M |
| Working Capital | $16.24M | $76.81M |
Financial position
| Measure | In8bio | Industry median |
|---|---|---|
| Current Ratio | 8.21 | 3.34 |
| Quick Ratio | 7.97 | 2.44 |
Cash flow (trailing twelve months)
| Measure | In8bio | Industry median |
|---|---|---|
| Operating Cash Flow | -$14.36M | -$12.35M |
Efficiency
| Measure | In8bio | Industry median |
|---|---|---|
| Profits Per Employee | -$1.10M | -$703.34K |
| Employee Count | 17 | 74 |
Dividends and yields
| Measure | In8bio | Industry median |
|---|---|---|
| Earnings Yield | -173.7% | -23.3% |
| Buyback Yield | -11.3% | -0.59% |
| Shareholder Yield | -11.3% | 0.00% |
Shares
| Measure | In8bio | Industry median |
|---|---|---|
| Shares Outstanding | 9,858,380 | 58,127,000 |
| Shares Change (YoY) | 365.4% | 10.9% |
| Shares Change (QoQ) | 0.06% | 0.54% |
| Shares Held by Institutions | 38.4% | 59.4% |
Scores
| Measure | In8bio | Industry median |
|---|---|---|
| Altman Z-Score | -9.75 | -0.22 |
| Piotroski F-Score | 4 | 4 |
Calculated by StockData from In8bio's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.